Navigation Links
Drugs May Help Healthy Men Lower Prostate Cancer Risk
Date:2/24/2009

New guidelines suggest that men discuss use of medicines such as Propecia with their doctor

TUESDAY, Feb. 24 (HealthDay News) -- Healthy men with no signs of prostate cancer may wish to talk to their doctors about taking a drug that could further reduce their risk for the disease, new guidelines suggest.

The American Society of Clinical Oncology and the American Urological Association have issued new guidelines recommending that these men talk to their doctors about using a 5-alpha reductase inhibitors (5-ARI). These drugs -- which include finasteride (Propecia), used to treat male pattern baldness -- can reduce levels of dihydrotestosterone (DHT), a hormone that spurs prostate cancer development.

Previous studies have been shown that 5-ARIs reduce risk of contracting the illness by 25 percent.

Prostate cancer is the second-leading cause of death by cancer in men.

"Although one in every six men in the United States will be diagnosed with prostate cancer, we are not recommending that all men take 5-ARIs," co-chair of the guideline panel Dr. Barnett S. Kramer, associate director for disease prevention at the National Institutes of Health, stressed in a news release issued by the organizations. "However, we would encourage men to begin a dialogue with their doctors to determine if they could benefit from taking 5-ARIs to reduce their prostate cancer risk."

The guidelines call for doctors to discuss the pro and cons of a 5-ARI with male patients who score a 3.0 or lower on a prostate-specific antigen (PSA) test, show no signs of prostate cancer, and receive (or plan to receive) regular disease screening.

The guidelines also suggest that men already taking a 5-ARI for other conditions should discuss continuing the medication as a way to prevent prostate cancer. Today, 5-ARIs are used to treat male-pattern baldness and benign prostatic hyperplasia (enlarged prostate) among other non-cancerous conditions.

While supporting the guidelines, panel co-chair Dr. Paul F. Schellhammer noted that while 5-ARIs may decrease the risk of getting prostate cancer, it is not known whether these drugs reduce death from the disease.

"However, the demonstrated effect of 5-ARIs in reducing prostate cancer incidence makes it reasonable to recommend them for use to prevent the disease," he said in the same news release.

The guidelines are scheduled to appear in the March issue of the Journal of Clinical Oncology and The Journal of Urology.

More information

The U.S. National Cancer Institute has more about prostate cancer.



-- Kevin McKeever



SOURCE: American Society of Clinical Oncology/American Urological Association, news release, Feb. 24, 2009


'/>"/>
Copyright©2009 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Finding May Lead to New Drugs for Urinary Infections
2. Rheumatoid Arthritis Drugs Raise Shingles Risk
3. Asthma drugs need to be maintained for continued benefit
4. Doctors Guide to Cancer Drugs May Need Revising
5. Patient Savings on Prescription Drugs Reach Record High for 2008, Goal Announced for 2009
6. New guidelines for prescribing opioid pain drugs published
7. New Guidelines for Prescribing Opioid Pain Drugs Published
8. New guideline for prescribing opioid pain drugs published
9. Fertility Drugs Do Not Increase Ovarian Cancer Risk
10. drugstore.com inc. Reports Profitable Fourth Quarter of 2008 and Free Cash Flow of $5.4 Million on Record OTC Sales
11. Drugs from Biogen Idec and Merck are the Most Promising Therapies in Development in the Acute Heart Failure Market
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drugs May Help Healthy Men Lower Prostate Cancer Risk
(Date:12/8/2016)... ... 08, 2016 , ... California Senate Bill (SB) 863, signed into law in ... 2013 and 2014, according to CompScope™ Medical Benchmarks for California, 17th Edition , ... the study, medical payments per claim in California decreased 4 percent in 2013 and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... and financial planning services from offices headquartered in Hamilton County, is embarking on ... LuvFurMutts. , LuvFurMutts specializes in finding new homes for orphaned or neglected senior ...
(Date:12/8/2016)... ... December 08, 2016 , ... Coffey Agencies, a ... and commercial clients in the northern Alabama and Georgia regions, is embarking on ... 1977, Nobis Works has built a network of support and education facilities to ...
(Date:12/7/2016)... ... 2016 , ... Kenall Manufacturing, a leader in sealed healthcare lighting for more ... a multi-function, sealed, LED luminaire that meets the needs of everyone in the patient ... , A 2’ x 4’ model features four modes: reading, ambient, standard ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... S.L. (“Presence”) for a purchase price of approximately $17.4 million (net of ... annual revenue is approximately $13.2 million. Headquartered in Barcelona, Spain, Presence is ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... , Dec. 8, 2016  Valeant Pharmaceuticals ... TSX: VRX) ("Valeant") today announced positive results from ... study to assess the safety and efficacy of ... treatment of plaque psoriasis. Within ... with moderate to severe psoriasis, IDP-118 showed statistical ...
(Date:12/8/2016)... Mederi Therapeutics Inc . hat die behördliche Zulassung durch ... gastroösophageale Refluxerkrankung (GERD) – in China angekündigt. ... ... Live Stretta procedure performed and broadcast during ... Endoscopy at Wuhan Union Hospital ...
(Date:12/8/2016)...  Boehringer Ingelheim announced today that it has been ... is the ninth time that the company received a ... Place to Work for LGBT Equality. Administered by the ... benchmarking report on corporate policies and practices related to ... employees. "We are committed to creating ...
Breaking Medicine Technology: